Shares of Iovance Biotherapeutics surged as much as 10.2% to $10.87 on September 17 after Barclays analyst Etzer Darout raised his price target from $13 to $15 while keeping an Overweight (buy-equivalent) rating. The move caps a blistering 33% rally over five sessions from $8.14 and sets up a critical question: whether the company's cancer-cell therapy can break into the massive lung cancer market and justify a valuation that still trails most analyst targets.
• A Steady Drumbeat of Upgrades Signals Growing Wall Street Conviction. Barclays has raised its Iovance target five times since November 2025, when it sat at just $4.
The latest increase was driven by a physician survey that strengthened the analyst's positive view ahead of an expected fourth-quarter data update from Iovance's lung cancer trial.
Barclays highlighted the durability of the therapy's response as a potential differentiator. The stock still trades at a roughly 38% discount to Barclays' new target, meaning the analyst believes there is substantial room left to run.
• Lung Cancer Approval Could Transform the Revenue Picture. Iovance's cell therapy is already sold as Amtagvi for advanced melanoma, but the company is testing the same therapy in previously treated lung cancer, where 26% of patients saw tumors shrink or disappear with responses lasting beyond two years.
A potential U.S. accelerated approval and launch is targeted for the second half of 2027. Lung cancer dwarfs the melanoma market in patient volume, so even modest uptake would meaningfully widen the revenue base.
• Record Sales and Improving Margins Show the Core Business Is Gaining Traction. Iovance posted record Q2 2026 revenue of approximately $99.3 million with gross margins climbing to 56%.
The company is reviewing its previously issued 2026 guidance of $350–$370 million after stronger-than-expected demand.
It has expanded to more than 95 authorized treatment centers, with at least 110 expected by year-end.
• Cash Runway Remains a Key Risk Investors Must Watch. Iovance guides for its current cash to last only into early 2028 , which means the company may need to raise money — potentially diluting existing shareholders — before reaching profitability. The biotech sector tailwind (XBI +2.55%) provides a helpful backdrop, but Iovance's story ultimately hinges on whether lung cancer data and accelerating melanoma sales can close the gap between promise and profit.